ABSTRACT (309/350): 48
Background 49
We have identified molecules that exhibit synthetic lethality in cells with loss of the neurofibromin 1 50 (NF1) tumor suppressor gene. However, recognizing tumors that have inactivation of the NF1 tumor 51 suppressor function is challenging because the loss may occur via mechanisms that do not involve 52 mutation of the genomic locus. Degradation of the NF1 protein, independent of NF1 mutation status, 53 phenocopies inactivating mutations to drive tumors in human glioma cell lines. NF1 inactivation may 54 alter the transcriptional landscape of a tumor and allow a machine learning classifier to detect which 55 tumors will benefit from synthetic lethal molecules. 56
57
Results 58
We developed a strategy to predict tumors with low NF1 activity and hence tumors that may 59 respond to treatments that target cells lacking NF1. Using RNAseq data from The Cancer Genome Atlas 60 (TCGA), we trained an ensemble of 500 logistic regression classifiers that integrates mutation status with 61 whole transcriptomes to predict NF1 inactivation in glioblastoma (GBM). On TCGA data, the classifier 62 detected NF1 mutated tumors (test set area under the receiver operating characteristic curve (AUROC) 63 mean = 0.77, 95% quantile = 0.53 -0.95) over 50 random initializations. On RNA-Seq data transformed 64 into the space of gene expression microarrays, this method produced a classifier with similar 65 performance (test set AUROC mean = 0.77, 95% quantile = 0.53 -0.96). We applied our ensemble 66 classifier trained on the transformed TCGA data to a microarray validation set of 12 samples with 67 matched RNA and NF1 protein-level measurements. The classifier's NF1 score was associated with NF1 68 protein concentration in these samples. 69
70
Conclusions 71
We demonstrate that TCGA can be used to train accurate predictors of NF1 inactivation in GBM. The 72 ensemble classifier performed well for samples with very high or very low NF1 protein concentrations 73 but had mixed performance in samples with intermediate NF1 concentrations. Nevertheless, high-74
performing and validated predictors have the potential to be paired with targeted therapies and 75 personalized medicine. 76 77
BACKGROUND: 78
Genomic tools allow investigators to devise therapies targeting specific molecular abnormalities in 79 tumors. One such alteration is the loss of neurofibromin 1 (NF1), an important tumor suppressor that 80 regulates the activity of RAS GTPases [1, 2] . Heterozygous mutation or deletion of NF1 causes 81 neurofibromatosis type 1 (NF), one of the most frequently inherited genetic disorders [3] . NF patients 82 often develop plexiform neurofibromas (PNs), benign nerve tumors for which the only therapy is 83 surgery. However, resection is often impossible due to the tumor's intimate association with peripheral 84 and cranial nerves [4] . PNs can transform to malignant peripheral nerve sheath tumors (MPNSTs), which 85 are chemo-and radiation-resistant sarcomas with a dismal 20% 5-year survival [5] . In addition, patients 86 with NF are susceptible to a broad spectrum of other tumors including low-grade/pilocytic 87 astrocytomas, pheochromocytomas, optic nerve gliomas, and juvenile myelomonocytic leukemias [6] . 88
Many aggressive non-NF associated (sporadic) tumors have recently been shown to harbor NF1 89 mutations, including glioblastoma (GBM), neuroblastoma, melanoma, thyroid, ovarian, breast, and lung 90 cancers [7] . Therefore, somatic and inherited loss of NF1 function is emerging as a driver of tumors from 91 different organ sites. 92
Several groups including our own have been working to develop therapeutic approaches to target 93 tumors with loss of NF1. Previously, our lab developed a high throughput approach using yeast and 94 mammalian screening platforms to identify tool compounds and drug targets for cancer cells in which 95 NF1 loss drives tumor formation. Our pipeline identified small molecules that selectively kill or stop the 96 growth of MPNST cells carrying a mutation in NF1 or yeast lacking the NF1 homolog IRA2 [8] . We also 97 developed an assay in yeast to identify the targets of our lead tool compounds and found that one of 98 these compounds (UC-1) shares a mechanism (phosphorylation of RNA Pol II CTD Ser2/5) with 99 experimental drugs in clinical trials [8] . UC-1 impacts CTD phosphorylation, which is regulated by the 100 CTD kinase Ctk1, the yeast homolog of human Cdk9. We showed that deletion of CTK1 was synthetic 101 lethal with loss of the yeast NF1 homolog IRA2. Furthermore, we have found that inhibitors of this 102 process (dinaciclib, SNS-032) can inhibit other types of RAS-dysregulated tumor cells [9] . 103 However, relying on genetic data alone to identify tumors that may be susceptible to therapies 104 targeting NF1 loss may leave a proportion of potentially actionable tumors unrecognized. NF1 tumor 105 suppressor activity can be lost via mutation of the genomic locus, proteasome-mediated degradation, 106 inhibition by miRNA, de novo insertion of an ALU element, and C→U editing of the NF1 mRNA [10] [11] [12] [13] [14] . 107
This complexity presents challenges when trying to identify tumors that will benefit from molecules that 108 exert synthetic lethality with dysregulation of NF1/RAS pathways. 109
The Cancer Genome Atlas (TCGA) has released a large volume of data on several cancer tissues 110 measured on a variety of genomic platforms. In the present study, we leverage TCGA GBM RNAseq 111 expression data with matched mutation calls to construct a classifier capable of identifying an NF1 112 inactivation signature. This strategy sidesteps the problem of functional characterization of mutations 113 by evaluating a regulator's downstream gene expression activity. We applied this signature to predict 114 NF1 inactivation in a cohort of biobanked GBMs. In general, this approach can be translatable to any 115 gene producing measurable downstream transcriptome-wide effects. 116
117

METHODS: 118
The Cancer Genome Atlas Data used for building the classifier 119
We downloaded RNAseq and mutation data from TCGA Pan Cancer project from the UCSC Xena 120 data portal [15] and subset each dataset to only the GBMs [16] . The data consists of 607 GBMs; of which  121   291 have mutation calls, 172 have RNAseq measurements, and 149 have both RNAseq and mutation  122 calls. Of these 149 samples, 15 have inactivating NF1 mutations (10.1%) and were used as gold standard 123 positives in building the classifier ( Supplementary Table S1 ). Additionally, to reduce dimensionality while 124 avoiding unexpressed and invariant genes, we subset to the top 8,000 most variably expressed genes by 125 median absolute deviation. We z-scored all gene expression measurements. This resulted in the final 126 input matrix with dimension 149 samples by 8,000 genes. For use in platform independent predictions, 127 we used Training Distribution Matching (TDM) to transform the TCGA RNAseq data to match a 128 microarray expression distribution [17] . 129
Since we are also aware of the NF1 mutation status for each of the samples, we form a supervised 130 learning task -predicting when a sample has loss of NF1 activity. Our "X" matrix is formed by the 131 RNAseq measurements for all 149 samples measured by 8,000 genes, which are the features in the 132 model. Our "y" vector consist of {0, 1} elements where a 1 corresponds to a sample with an inactivating 133 NF1 mutation and a 0 is an NF1 wildtype sample. The machine learning task is to find the feature 134 weights, or gene coefficients, that best minimize our objective function. Along with these feature 135 weights corresponding to the genes' importance in the learning task, we also output a probability 136 estimate for each sample that they have loss of NF1 activity. 137 138
Hyperparameter optimization of the logistic regression classifier 139
Using the GBM RNAseq data, we trained logistic regression classifiers with an elastic net penalty 140 using stochastic gradient descent to detect tumors with NF1 inactivation. We chose a penalized 141 regression model because it is simple to train and has easily interpretable outputs including importance 142 scores for each gene (feature weights) associated with the downstream consequences of NF1 loss of 143 function and a probability for each sample that NF1 is lost. An elastic net logistic regression model has 144 also been successfully implemented in similar studies [18] [19] [20] . 145
We identified high-performing alpha and L1 mixing parameters using 5-fold cross validation ensuring 146 balanced membership of NF1 mutations in each fold. Briefly, alpha controls how weight penalty and the 147 L1 mixing parameter tunes the amount of test set regularization by controlling the sparsity of the 148
features. An L1 mixing parameter value of zero corresponds to the L2 penalty and a value of one 149 corresponds to the L1 penalty, with L1 bringing a sparser solution. We used python 3.5.1 and Sci-kit 150
Learn for machine learning implementations [21] . 151 152
Ensemble classifier construction and application to the validation set 153
After selecting optimal hyperparameters, we constructed 500 classifiers that would compose our 154 ensemble model. Specifically, across 100 different random initializations, we subset the full TCGA GBM 155 data into 5 folds and trained a single classifier for each training fold. 156
We borrowed terminology from the epidemiology field to describe data partitioning. We trained our 157 models on a "training" partition and assessed model performance on a "test" partition, which refers to 158 the held out cross-validation fold. The independent "validation set" refers to the GBM dataset 159 generated in a different lab (see Figure 1A ). 160
Because of the small number of gold standard positive training examples, we were concerned about 161 the stability of our model solutions. Therefore, we constructed an ensemble classifier from the 500 162 models. Specifically, we assigned each classifier a weight using the specific randomization's "test set" 163 cross-validation AUROC. Lastly, for the final NF1 inactivation prediction, we used the mean of the 164 weighted predictions across all iterations as the NF1 inactivation prediction. We applied this ensemble 165 classifier to the validation set in which NF1 protein levels were directly measured. 166 167
Effect sizes and power analysis 168
We calculated the decision function of each ensemble classifier applied to all samples in the 169 training and testing 5-fold cross validation folds to calculate Cohen's D effect size between predicted 170 NF1 wildtype and NF1 inactive samples [22] . The Cohen's D metric quantifies the difference between 171 NF1 wildtype and NF1 inactive samples according to the mean classifier score and directly demonstrates 172
how different the ensemble model predicts the two groups to be. 173
Moreover, we were also concerned that our relatively small validation set would not provide us 174 with enough power to observe a detectable effect in the ensemble model's final prediction. We 175 performed a one-tailed Welch's two-sample t-test comparing the NF1 protein concentration of our 176 validation samples that were predicted to be either NF1 wildtype or NF1 deficient. Using the given 177 We applied a quality control pipeline [27] to all CEL files generated by the HTA 2.0. All validation 235 samples passed processing quality control, which included an inspection of spatial artifacts, MA plots, 236 probe distributions, and sample comparison boxplots. We summarized transcript intensities using 237 robust multi-array analysis (RMA) [28] . We determined batch normalization was unnecessary after a 238 guided principal components analysis (gPCA) using sample processing date and array plate ID as 239 potential batch effect confounders [29] . Lastly, we collapsed HTA2.0 transcripts into gene level 240 measurements using the `collapseRows()` function with the "maxmean" method from the R package 241 WGCNA [30] . We used the pd.hta.2.0 platform design file (version 3.12.1) and the Bioconductor package 242 "hta20sttranscriptcluster.db" (version 8.3.1) to map manufacturer transcript IDs to genes. We 243 performed all preprocessing steps using R version 3. 
RESULTS: 284
Classifier performance 285
Using 5-fold cross validation across a parameter sweep, we identified optimal hyperparameters 286 at alpha = 0.15 and L1 mixing = 0.1 (Supplementary Figure S1 ). To assess model performance, we 287 performed 100 random initializations of five-fold cross-validation. These models had mean test area 288 under the receiver operating characteristic curve (AUROC) of 0.77 (95% Quantiles: 0.53 -0.95) and a 289 mean train AUROC of 0.997 (95% Quantile: 0.98 -1.00) (Supplementary Figure S2) . We repeated this 290 procedure after TDM transformation (Supplementary Figure S3 ) and achieved comparable results with 291 alpha = 0.15 and l1 mixing = 0.1 (mean test AUROC = 0.77, 95% Quantiles: 0.51 -0.96; mean train 292 AUROC = 0.998, 95% Quantiles: 0.99 -1.00) ( Figure 1B) . Because the validation set was measured by 293 microarray, we used the classifier trained on TDM transformed data to construct our ensemble 294 classifier. We also determined the Cohen's D effect size estimate for all training and testing partitions 295 across all 5-fold cross validation iterations of the TDM transformed model ( Supplementary Fig S4) . The 
Identification and characterization of NF1 deficient glioblastoma tumor samples 312
We characterized NF1 protein concentrations as well as other molecules involved in RAS signaling in 313 the 12 GBM samples (Figure 2A ). Two samples (CB2, 3HQ) had no apparent NF1 protein. Eight other 314 samples had similar or less NF1 signal than the U87-MG NF1-low control (H5M, LNA, YXL, VVN, R7K, 315 TRM, UNY, W31). Two samples (PBH, RIW) had equal or greater NF1 than the positive control, U87-MG + 316 proteasome inhibitors (preventing NF1 degradation). We also observed variable EGFR content in these 317 samples, with non-existent to low levels (3HQ, YXL, R7K), or medium to large EGFR signal (CB2, H5M, 318 PBH, LNA, YXL, VVN, RIW, TRM, UNY, W31). All GBM samples had high concentrations of phospho-319 ERK1/2 signal relative to cell line controls. Samples with increased phospho-ERK1/2 may have greater 320 Ras pathway activation. This can be attributed to multiple factors, including increased EGFR expression 321 and/or NF1 inactivation. 322
Our ensemble classifier predicted four samples to have NF1 inactivation (CB2, UNY, R7K, and 3HQ) 323 and eight samples to be NF1 wildtype (W31, TRM, PBH, VVN, LNA, RIW, H5M, and YXL) ( Figure 2B) . 324
Because two samples, (CB2 and H5M) were measured on both western blots ( Figure 2C) , we used the 325 mean of their NF1 protein level across both experiments. 326
We performed a one-tailed Welch's t-test to determine if NF1 protein concentrations were 327 significantly higher in NF1 wildtype versus NF1 deficient samples based on our classifier predictions 328 ( Figure 2D ). We did not observe a significant difference across groups (t = -1.38, p = 0.098, effect size = 329 0.699). Additionally, while the effect size was fairly large, a power analysis indicated that 22 samples per 330 group would be required to achieve a power = 0.8 at that effect size. With a lack of glioblastoma 331 samples with quantified NF1 protein available, the trend of less protein present in samples scored as 332
NF1 inactivated by the classifier nevertheless remains promising. 333
One of the samples predicted to be NF1 inactive contains detectable NF1 protein (R7K), suggesting 334 that this sample may have NF1 inactivation not detectable by assaying protein, have a different 335 alteration that phenocopies NF1 loss, or is incorrectly predicted by the classifier. Conversely, there are 336 three samples predicted to be NF1 wildtype that have low or undetectable protein (YXL, VVN, W31), 337 which either indicates unknown elements that confound the detection of some NF1 dysregulated 338 tumors or a classification error. 339 
Highly Contributing Genes 352
We observed several genes that consistently contributed to the ensemble classifier performance 353 ( Figure 3 ). Since we applied several classifiers to the validation set as an ensemble, we took the sum of 354 all classifier's gene weights across all 500 iterations to define these consistently contributing genes. 355
While the data indicate that these genes have an impact on classifier performance, the data do not 356 indicate whether changes in the expression of these genes are a direct consequence in changes in NF1 357 signaling. Expression of genes such as TXNIP, ARRDC4, ISPD, C10orf107, and DUSP18 appear to be 358 predictive of intact NF1 signaling. Among the list of genes that appear to be expressed in tumors with 359 loss of NF1 function are QPRT, ATF5, HUS1B, PEG10, HMGA2, RSL1D1, and NRG1. A full list of positive 360 and negative weight genes that were two standard deviations beyond the gene weight distribution is 361 provided in Supplementary Table S2 . 362 363 Figure 3 : Genes that contribute to the classifier performance. Genes are shown ranked by their weighted 364 contribution to the ensemble classifier. Weights are scaled to unit norm. The top 10 positive and top 10 365 negative contributing high weight genes are given on the right. 366 367
We also performed over-representation analysis of the most influential genes in the classifier to 368 identify gene ontology (GO) sets and pathways that may be predictive of NF1 status [33-36]. S3For high-369
weight genes predictive of intact NF1 signaling, we observed GO sets involved in plasma membrane-370 localized proteins (GO:0005886, GO:0071944, GO:0016324) and homeostasis (GO:0048871, 371 GO:0001659, GO:0048873, GO:0031224), among others. Annotated pathways associated with genes 372 from this dataset include hematopoietic stem cell differentiation, thyroid cancer, voltage-gated 373 potassium channels, and RHO GTPase functional pathways. 374
For high-weight genes predictive of NF1 loss of function, we observed GO sets related to cellular 375 adhesion (GO:0007155, GO:0098742), negative regulation of signaling (GO:0009968, GO:0023507, 376 GO:0010648), and nervous system development (GO:0051962, GO0007416, GO: 0050808), among 377 others. These genes were also enriched for elements of the phototransduction cascade and thyroxine 378 production pathways. rapidly growing library of datasets, the performance of machine learning models is likely to rapidly 390
improve. An increase in performance leads to more reliable clinical applications that would potentially 391 predict the effectiveness of pathway-specific targeted therapies. 392
While our classifier was able to predict NF1 inactivation status to an extent, its performance is far 393 from being clinically actionable. A major difficulty in developing a reliable classifier in this case is 394 contamination in gold standard positives and negatives. While we aim to detect NF1 inactivation events, 395 our gold standard positives can only include samples with known NF1 mutation status. Conversely, we 396 expect that negative samples (about 90% of the data) are also contaminated with NF1 inactivated 397 samples due to protein loss and other mechanisms. We cannot determine scenarios where NF1 is 398 inactivated beyond mutation at scale in the TCGA data. Another challenge with the construction of 399 classifiers from such data is overfitting. Even after hyperparameter optimization we observed 400 substantial overfitting (Figure 2 ), which has also been observed in competitions (see, for example, 401 supplementary figure S2 of Noren et al. 2016 [42] in which the best performing algorithms also overfit). 402
Finally with a small number of positive examples the model performance is unstable, which 403 demonstrates high variability in gold standard samples used to train the model [43] . We employed 404 ensemble classification to mitigate this issue as averaging over heterogeneous models would result in a 405 relatively stable classifier (see Figure 2B ). In summary, our results are promising but these challenges are 406 substantial and significant work remains to reach a robust classifier with clinical utility. 407
The performance of the classifier appears to be impacted by many cancer related genes. For 408 example, genes such as TXNIP and ARRDC4, which are both indicative of lactic acidosis, correlate with 409 better clinical outcomes, and contribute to predicting tumors with intact NF1 signaling [44] . We also 410 observed transcripts that are more highly expressed in brain tissue than either other normal tissue 411 (ISPD, C10orf107), or more highly expressed in normal brain tissue than glioma (EPHA5) [45] [46] [47] . 412 DUSP18 contributes to the prediction of NF1 wildtype status and is a negative regulator of ERK 413 phosphorylation, possibly by regulating SHP2 phosphorylation [48] . It is unclear whether the expression 414 of these genes is a direct result of NF1 expression, the result of signaling downstream of NF1, or a 415 consequence of other phenomena (such as expression of SPRED1, an NF1 binding partner that is 416 essential for NF1 signaling). Future studies could elucidate the potential connections between NF1 and 417 the genes identified as important for the performance of this classifier. 418
Over-representation analysis of these data highlighted changes in potassium channel expression. It 419 was previously demonstrated that NF1 wild-type Schwann cells have altered K+ channel activity as 420 compared to NF1 -/-Schwann cells suggesting that this may be one factor by which NF1 mutant and wild-421 type cells can be distinguished [49] . 422
Regarding prediction of NF1 inactivated tumors, we observed several genes that have been linked to 423 cancer such as QPRT, which is highly expressed in malignant pheochromocytomas as compared to 424 benign; RSL1D1 (CSIG), which stabilizes c-myc in hepatocellular carcinoma; PPEF, which is highly 425 expressed in astrocytic gliomas as compared to normal brain tissue [50-52]; and PEG10, a poor 426 prognostic marker and regulator of proliferation, migration, and invasion in several tumor types [53] [54] [55] . 427
We also observed ATF5, a gene for which expression in malignant glioma is correlated with poor survival 428 [63], poor classifier generalizability, or incomplete data transformation between RNAseq and microarray 440 data. Because training and testing performance were similar between transformed and non-441 transformed data (see Figure 1 and Supplementary Fig S2) we don't anticipate performance to be 442 impacted much by platform differences or classifier generalizability. Nevertheless, we demonstrated the 443 ability of system-wide gene expression measurements to capture downstream consequences of a 444 complex biological mechanism that would otherwise require several different types of data acquisition 445 to capture. 446 447
CONCLUSIONS: 448
A machine learning classifier for transcriptomic data was able to detect signal associated with the 449 inactivation of NF1, a tumor suppressor gene. The gene is an important regulator of the oncogene RAS 450 and is inactivated frequently in GBM and in other tumors. The measurement of NF1 inactivity cannot be 451 comprehensively captured by any single genomic characterization such as targeted sequencing or 452 fluorescence in situ hybridization. This difficulty arises from diverse and complex biological mechanisms 453 that inactivate the tumor suppressor in a variety of ways. However, we demonstrated that measuring 454 system-wide RNA can capture subtle downstream changes that occur in response to NF1 inactivation. 455 Improving classification performance is required before transitioning such a model into clinical use, but 456 our method could be used to characterize cell lines or patient-derived xenograft (PDX) models with 457 inactive NF1. Eventually, with more data and improved classification, we expect machine-learning 458 models constructed on system-wide transcriptomics will translate into clinically relevant predictions that 459 will guide targeted therapy. 
